View Older Stories View More Recent Stories
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS), PT $37, 'Q4 revenues tracking below guidance and consensus'
-
Hims and Hers (HIMS) PT Lowered to $41 at Leerink Partners
-
Hims & Hers expands into Canada through Livewell acquisition
-
HIMS enters Canada market through Livewell acquisition
-
Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
-
Hims & Hers appoints Deb Autor as first chief policy officer
-
HIMS launches Labs testing service with two pricing tiers
-
Truist: 'Klarna Partnership Aligns with HIMS' Focus on Improving Affordability'
-
Hims & Hers Health, Inc. (HIMS) To Offer Lab Testing To Boost Growth - DJ
-
Morgan Stanley on Hims and Hers (HIMS): 'October Data Continues to Trend in the Wrong Direction'
-
Needham: 'GLP-1 Price Cuts Limit HIMS Competitive Advantage'
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'
-
Hims and Hers (HIMS) PT Raised to $46 at Leerink Partners
-
KeyBanc: 'Hims and Hers (HIMS) Setting the Stage for Future Growth'
-
Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'
-
Hims and Hers (HIMS) PT Raised to $32 at BofA Securities
-
BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'
-
Canaccord Genuity Reiterates Buy Rating on Hims and Hers (HIMS)
-
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
-
Hims & Hers in talks with Novo Nordisk to offer Wegovy treatments
-
Hims & Hers Health, Inc. (HIMS) Misses Q3 EPS by 4c, Offers Guidance
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put into quarter results
-
TD Cowen on Hims and Hers (HIMS): 'Decelerating Trends; Lack of Upside Likely'
-
KeyBanc Starts Hims and Hers (HIMS) at Sector Weight
-
Hims & Hers CEO Dudum comments on Grail investment
-
BofA: 'We maintain our Underperform rating on HIMS due to growing competition, but view this morning’s news positively'
-
Hims & Hers launches menopause treatment services
-
Hims & Hers to Offer Treatments for Menopause, Perimenopause - DJ
-
BofA Negative on Hims and Hers (HIMS): 'Lowering 4Q sales and full year below the guidance range'
-
Hims & Hers releases customer survey data on telehealth care quality
-
Hims & Hers CEO Dudum announces COO change, appointing Mike Chi
-
Hims & Hers names Mike Chi as new COO as Nader Kabbani transitions
-
BofA Reiterating Negative View on Hims and Hers (HIMS): '3Q beat less likely, order growth under more pressure'
-
Survey shows 1/3 of GLP-1 users are lower-income
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
GoodRx (GDRX) Lower on Report Trump Officials Weigh Website To Help Shop For Cheaper Drugs
-
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum: around 100 FDA letters went out last week to companies across the industry, we got one
-
FDA issues warning letter to HIMS over semaglutide marketing claims
-
CMS Launches Landmark $50 Billion Rural Health Transformation Program
-
BofA Securities on Hims and Hers (HIMS): 'Dr. Makary’s op-ed in the New York Times is a negative for HIMS'
-
Hims & Hers shares drop after FDA chief flags ad violations
-
Canaccord Genuity Positive on Hims and Hers (HIMS): 'we see several paths to FY30 targets'
-
BTIG Remains Positive Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) 'given near-term competitive pressures in the core business'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
-
Hims and Hers (HIMS) PT Lowered to $37 at Truist Securities
-
Hims and Hers (HIMS) July orders fall further - BofA
